Systolic Blood Pressure Intervention Trial (SPRINT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01206062|
Recruitment Status : Completed
First Posted : September 21, 2010
Results First Posted : December 4, 2017
Last Update Posted : January 8, 2021
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Intensive control of SBP Drug: Standard control of SBP||Not Applicable|
SPRINT strived to enroll about 9250 participants aged ≥ 50 years with SBP ≥130 mm Hg and at least one additional CVD risk factor. The trial compared the effects of randomization to a treatment program of an intensive SBP goal with randomization to a treatment program of a standard goal. Target SBP goals were <120 vs <140 mm Hg, respectively, to create a minimum mean difference of 10 mm Hg between the two randomized groups. The primary hypothesis was that CVD event rates would be lower in the intensive arm. Participants were recruited at approximately 90 clinics within 5 clinical center networks (CCNs) over approximately a 2-year period, and were followed for 4-6 years.
A total of 9361 participants were enrolled. NIH stopped the blood pressure intervention earlier than originally planned in order to quickly disseminate the significant preliminary results. Follow-up for cognitive and kidney outcomes continues during the post-intervention phase through May 2018.
|Study Type :||Interventional|
|Actual Enrollment :||9361 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Systolic Blood Pressure Intervention Trial|
|Actual Study Start Date :||October 2010|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||March 2019|
Experimental: Intensive Control of SBP
Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic "milepost" visits: addition of another drug "required" if not at goal.
Drug: Intensive control of SBP
Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics
Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.
Active Comparator: Standard Control of SBP
Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
Drug: Standard control of SBP
Participants in the Standard BP arm have a goal of SBP <140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Other Name: Control of SBP to a target of 140 mm Hg
- Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death [ Time Frame: 6 years ]
- Number of Participants With All-cause Mortality [ Time Frame: 6 years ]
- Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR [ Time Frame: 6 years ]
- Participants Who Developed End Stage Renal Disease [ Time Frame: 6 years ]
- Number of Patients With All-cause Dementia [ Time Frame: 6 years ]A 3-step process was used ascertain incident cases of all-cause dementia. First, to identify possible cases of dementia a brief Cognition Screening Battery was administered to all participants. Participants who score below the pre-designated screening cut-point for possible cognitive impairment during follow-up were administered a more comprehensive and detailed neurocognitive test battery (the Extended Cognitive Assessment Battery) plus the Functional Assessment Questionnaire (FAQ) which assesses impairments in daily living skills as a result of cognitive impairments. Last, all the above available tests and questionnaire data were submitted to a centralized, web-based system for adjudication by a panel of dementia experts who assigned final study classifications of probable dementia (PD), mild cognitive impairment (MCI) or no impairment (NI).
- Small Vessel Cerebral Ischemic Disease [ Time Frame: 4 years ]
Change over 4 years in total white matter lesion volume from baseline Change over 4 years in total brain volume from baseline
Because of the skewed distribution for WML volume, we first applied an inverse hyperbolic sine transformation (asinh), which is similar to a log transformation but can accommodate values of zero. Linear mixed models, including random effects for participant and MRI facility, were used to estimate the change in WML volume and TBV between the treatment groups, including time since randomization (in days) and intracranial volume as covariates. Because the inverse hyperbolic sine transformation is nonlinear, and given the context of a mixed-effects model, back-transformation to the original scale of cm3 is difficult
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01206062
|United States, North Carolina|
|Wake Forest University School of Medicine|
|Winston-Salem, North Carolina, United States, 27157|
|Principal Investigator:||David M. Reboussin, PhD||Wake Forest University Health Sciences|
|Principal Investigator:||Jackson T Wright, MD||Case Western Reserve University|
|Principal Investigator:||Alfred Cheung, MD||University of Utah|
|Principal Investigator:||Suzanne Oparil, MD||University of Alabama at Birmingham|
|Principal Investigator:||Mike Rocco, MD||Wake Forest University Health Sciences|
|Principal Investigator:||Bill Cushman, MD||Memphis VA Medical Center|